3-氯-4-氟苯乙醇 | 340825-21-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氯-4-氟苯乙醇
• 中文别名: 2-(3-氯-4-氟苯基)乙醇
• 英文名称: 2-(3-Chloro-4-fluorophenyl)ethanol
• CAS: 340825-21-0
• 化学式: C₈H₈ClFO
• 分子量: 174.6
• InChiKey: ZLWGTYVDMGWYEM-UHFFFAOYSA-N

物化性质

• 沸点：
  251.4±25.0 °C(Predicted)
• 密度：
  1.284±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H317,H319

反应信息

• 作为反应物：
  描述：

  3-氯-4-氟苯乙醇 、 碘代醋酸乙酯 、 2,6-二叔丁基吡啶 在 silver trifluoromethanesulfonate 作用下， 以to give [2-(3-chloro-4-fluoro-phenyl)-ethoxy]-acetic acid ethyl ester as colorless oil的产率得到[2-(3-chloro-4-fluoro-phenyl)-ethoxy]-acetic acid ethyl ester
  参考文献：
  名称：

  Novel pyridopyprimidinone derivatives which are HM74A agonists

  摘要：

  本发明涉及式(I)的新型吡啶吡咯啉酮衍生物：其中R1至R8，X，Y，m和n如描述和权利要求所定义。本发明的化合物是HM74A激动剂，与烟酸相比具有改善的性能，并可用于治疗和/或预防与HM74A相关的疾病，如血脂异常，动脉粥样硬化，糖尿病，代谢综合征和其他相关疾病。

  公开号：

  US20070275987A1

文献信息

• Novel pyridopyprimidinone derivatives which are HM74A agonists
  申请人：Conte Aurelia

  公开号：US20070275987A1

  公开（公告）日：2007-11-29

  The invention is concerned with novel pyridopyrimidinone derivatives of formula (I): wherein R 1 to R 8 , X, Y, m and n are as defined in the description and in the claims. The compounds of the present invention are HM74A agonists with improved properties compared to niacin and can be used for the treatment and/or prevention of diseases such as dyslipidemia, atherosclerosis, diabetes, metabolic syndrome, and other related diseases associated with HM74A.

  这项发明涉及式(I)的新型吡啶吡嘧啶酮衍生物：其中R1至R8、X、Y、m和n如描述和索赔中所定义。本发明的化合物是HM74A激动剂，与烟酸相比具有改进的性能，并可用于治疗和/或预防与HM74A相关的疾病，如脂质代谢异常、动脉粥样硬化、糖尿病、代谢综合征和其他与HM74A相关的疾病。
• NOVEL AZA-PYRIDOPYRIMIDINONE DERIVATIVES
  申请人：Conte Aurelia

  公开号：US20080234277A1

  公开（公告）日：2008-09-25

  The invention is concerned with novel aza-pyridopyrimidinone derivatives of formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 , X 1 , X 2 , X 3 , Y, Z, m and n are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds are HM74A agonists and can be used in treating or preventing diseases which are modulated by HM74A agonists.

  本发明涉及式（I）的新型氮杂吡啶嘧啶酮衍生物：其中R1、R2、R3、R4、R5、X1、X2、X3、Y、Z、m和n如描述和权利要求中所定义，以及其生理上可接受的盐和酯。这些化合物是HM74A激动剂，可用于治疗或预防由HM74A激动剂调节的疾病。
• Pyridopyrimidinone derivatives which are HM74A agonists
  申请人：Hoffmann-La Roche Inc.

  公开号：US07572801B2

  公开（公告）日：2009-08-11

  The invention is concerned with novel pyridopyrimidinone derivatives of formula (I): wherein R1 to R8, X, Y, m and n are as defined in the description and in the claims. The compounds of the present invention are HM74A agonists with improved properties compared to niacin and can be used for the treatment and/or prevention of diseases such as dyslipidemia, atherosclerosis, diabetes, metabolic syndrome, and other related diseases associated with HM74A.

  本发明涉及公式（I）的新型吡啶吡嗪酮衍生物：其中R1至R8、X、Y、m和n如说明书和权利要求所定义。本发明的化合物是HM74A激动剂，与烟酸相比具有改善的性质，可用于治疗和/或预防与HM74A相关的疾病，如血脂异常、动脉硬化、糖尿病、代谢综合征和其他相关疾病。
• AGONISTS OF GPR131 AND USES THEREOF
  申请人：Novack Aaron Robert

  公开号：US20130059856A1

  公开（公告）日：2013-03-07

  Chemical compounds which act as agonists of, or otherwise modulate the activity of, GPR131 are disclosed. Related compositions, formulations and methods of use are also described.

  本文披露了作为GPR131激动剂或其他方式调节其活性的化合物。还描述了相关的组合物、制剂和使用方法。
• PYRIDOPYRIMIDINONE DERIVATIVES
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2029601B1

  公开（公告）日：2010-06-02